Upon regulatory success in EU and US assuming a 5 per 100k incidence of IIH at 50% market penetration and 10 per 100k prevalence of IIH at 20% market penetration I had done some numbers at a peak sales multiple of 3x that this would be worth about 2.5bil. Obviously a long way from there and I doubt it will make it that far but I don't see anything south of 500m as a reasonable buyout assuming regulatory approval in EU. Just a forecast, anyway.
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-153
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17222 | 9.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 6250 | 2 |
View Market Depth
| Last trade - 16.12pm 01/11/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable